Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Public ClinicalTrials.gov record NCT04697628. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.
Study identification
- NCT ID
- NCT04697628
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 502 participants
Conditions and interventions
Conditions
Interventions
- tisotumab vedotin Drug
- topotecan Drug
- vinorelbine Drug
- gemcitabine Drug
- irinotecan Drug
- pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2021
- Primary completion
- Jul 23, 2023
- Completion
- Jan 14, 2026
- Last update posted
- Feb 23, 2026
2021 – 2026
United States locations
- U.S. sites
- 53
- U.S. states
- 15
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HAL | Glendale | Arizona | 85308 | — |
| Arizona Oncology Associates P.C. - NAHOA | Phoenix | Arizona | 85016 | — |
| Arizona Oncology Associates, PC - HAL | Phoenix | Arizona | 85016 | — |
| Arizona Oncology Associates, PC - HAL | Scottsdale | Arizona | 85258 | — |
| Arizona Oncology Associates, PC - HAL | Tempe | Arizona | 85284 | — |
| University of California Irvine Health | Irvine | California | 92697 | — |
| UC Irvine Health (Investigator Site File Location) | Orange | California | 92868 | — |
| University of California Irvine Health | Orange | California | 92868 | — |
| Olive View - UCLA Medical Center | Sylmar | California | 91342 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| Broward Health Medical Center | Fort Lauderdale | Florida | 33316 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Norton Cancer Institute, Downtown | Louisville | Kentucky | 40202 | — |
| Norton Hospital | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD | Louisville | Kentucky | 40207 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Norton Women's & Children's Hospital | Louisville | Kentucky | 40207 | — |
| Willis-Knighton Cancer Center Infusion Center | Shreveport | Louisiana | 71103 | — |
| Willis-Knighton Physician Network/ Hematology-Oncology Associates | Shreveport | Louisiana | 71103 | — |
| Willis-Knighton Physician Network/WK Gynecologic Oncology Associates | Shreveport | Louisiana | 71103 | — |
| Willis-Knighton Physician Network/WK Gynecologic Oncology Associates | Shreveport | Louisiana | 71118 | — |
| Minnesota Oncology Hematology PA | Coon Rapids | Minnesota | 55433 | — |
| Minnesota Oncology Hematology, P.A | Coon Rapids | Minnesota | 55433 | — |
| Minnesota Oncology Hematology, P.A | Edina | Minnesota | 55435 | — |
| Minnesota Oncology Hematology, P.A | Maplewood | Minnesota | 55109 | — |
| Minnesota Oncology Hematology, P.A | Minneapolis | Minnesota | 55404 | — |
| Minnesota Oncology Hematology, P.A | Saint Paul | Minnesota | 55102 | — |
| St. Dominic- Jackson Memorial Hospital Pharmacy Attn: Richard Wakefield | Jackson | Mississippi | 39216 | — |
| Washington University School of Medicine- Obstetrics & Gynecology [Academic Offices] | St Louis | Missouri | 63108 | — |
| Washington University School of Medicine [Patient Clinics] | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine-Obstetrics & Gynecology | St Louis | Missouri | 63110 | — |
| NewYork Presbyterian - Brooklyn Methodist Hospital | Brooklyn | New York | 11215 | — |
| NewYork Presbyterian - Queens | Flushing | New York | 11355 | — |
| NewYork Presbyterian - Queens | Forest Hills | New York | 11375 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone. | New York | New York | 10016 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| Cleveland Clinic Taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Fail·view Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic Fairview Hospital- Moll Cancer Center lnvestigational Pharmacy | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic Fairview Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic. | Cleveland | Ohio | 44195 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| OSU Wexner Medical Center, OSU Gynecologic Oncology at Mill Run | Hilliard | Ohio | 43026 | — |
| Cleveland Clinic Hillcrest Hospital | Mayfield Heights | Ohio | 44124 | — |
| Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| US Oncology lnvestigational Products Center (IPC) | Irving | Texas | 75063 | — |
| University of Virginia Comprehensive Cancer Center | Charlottesville | Virginia | 22903 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
| VCU Health, Investigational Drug Service (ATTN: Henly Deutsch, RPh) | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 158 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04697628, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04697628 live on ClinicalTrials.gov.